Waksal's Kadmon rapidly builds on hepatitis C franchise with Valeant deals
This article was originally published in Scrip
Executive Summary
Kadmon Pharmaceuticals, Samuel Waksal's new venture, is moving quickly to strengthen its hepatitis C franchise.